Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

496 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A non-interventional phase IV Belgian survey to assess the antiviral effectiveness of pegylated interferon-alpha-2b and ribavirin treatment according to the stage of liver fibrosis in previously untreated patients with genotype 1/4/5/6 chronic hepatitis C (PRACTICE).
Bourgeois S, Deltenre P, Delwaide J, Henrion J, Adler M, Langlet P, Mulkay JP, Nevens F, Brixko C, Moreno C. Bourgeois S, et al. Among authors: nevens f. Acta Gastroenterol Belg. 2014 Dec;77(4):393-400. Acta Gastroenterol Belg. 2014. PMID: 25682628 Free article. Clinical Trial.
Effectiveness and tolerability of pegylated interferon alfa-2b in combination with ribavirin for treatment of chronic hepatitis C: the PegIntrust study.
Van Vlierberghe H, Adler M, Bastens B, Colle I, Delwaide J, Henrion J, Horsmans Y, Michielsen P, Golstein P, Mulkay JP, Van Steenbergen W, Yap P, Nevens F, Denys AM, Brasseur JP. Van Vlierberghe H, et al. Among authors: nevens f. Acta Gastroenterol Belg. 2010 Jan-Mar;73(1):5-11. Acta Gastroenterol Belg. 2010. PMID: 20458844 Free article.
A randomized, open-label, multicenter study evaluating the efficacy of peginterferon alfa-2a versus interferon alfa-2a, in combination with ribavirin, in naïve and relapsed chronic hepatitis C patients.
Nevens F, Van Vlierberghe H, D'Heygere E, Delwaide J, Adler M, Henrion J, Lenaerts A, Hendlisz A, Michielsen P, Bastens B, Brenard R, Laureys A; BERNAR-1 Study Group. Nevens F, et al. Acta Gastroenterol Belg. 2010 Apr-Jun;73(2):223-8. Acta Gastroenterol Belg. 2010. PMID: 20690560 Free article. Clinical Trial.
Hepatitis C virus: the burden of the disease.
Adler M, Goubau P, Nevens F, Van Vlierberghe H. Adler M, et al. Among authors: nevens f. Acta Gastroenterol Belg. 2002 Apr-Jun;65(2):83-6. Acta Gastroenterol Belg. 2002. PMID: 12148444 Review.
Daily induction combination treatment with alpha 2b interferon and ribavirin or standard combination treatment in naive chronic hepatitis C patients. A multicentre randomized controlled trial.
Van Vlierberghe H, Leroux-Roels G, Adler M, Bourgeois N, Nevens F, Horsmans Y, Brouwer J, Colle I, Delwaide J, Brenard R, Bastens B, Henrion J, de Vries RA, de Galocsy C, Michielsen P, Robaeys G, Bruckers L. Van Vlierberghe H, et al. Among authors: nevens f. J Viral Hepat. 2003 Nov;10(6):460-6. doi: 10.1046/j.1365-2893.2003.00466.x. J Viral Hepat. 2003. PMID: 14633181 Clinical Trial.
Clinical trial: a randomized trial of pegylated-interferon-alpha-2a plus ribavirin with or without amantadine in treatment-naïve or relapsing chronic hepatitis C patients.
Langlet P, D'Heygere F, Henrion J, Adler M, Delwaide J, Van Vlierberghe H, Mulkay JP, Lasser L, Brenard R, Horsmans Y, Michielsen P, Laureys A, Nevens F. Langlet P, et al. Among authors: nevens f. Aliment Pharmacol Ther. 2009 Aug 15;30(4):352-63. doi: 10.1111/j.1365-2036.2009.04052.x. Epub 2009 May 26. Aliment Pharmacol Ther. 2009. PMID: 19485978 Free article. Clinical Trial.
The risk of early occurrence and recurrence of hepatocellular carcinoma in hepatitis C-infected patients treated with direct-acting antivirals with and without pegylated interferon: A Belgian experience.
Bielen R, Moreno C, Van Vlierberghe H, Bourgeois S, Mulkay JP, Vanwolleghem T, Verlinden W, Brixco C, Decaestecker J, de Galocsy C, Janssens F, Van Overbeke L, Van Steenkiste C, D'Heygere F, Cool M, Wuyckens K, Nevens F, Robaeys G. Bielen R, et al. Among authors: nevens f. J Viral Hepat. 2017 Nov;24(11):976-981. doi: 10.1111/jvh.12726. Epub 2017 Aug 3. J Viral Hepat. 2017. PMID: 28504854
Belgian experience with triple therapy with boceprevir and telaprevir in genotype 1 infected patients who inject drugs.
Arain A, Bourgeois S, de Galocsy C, Henrion J, Deltenre P, d'Heygere F, George C, Bastens B, Van Overbeke L, Verrando R, Bruckers L, Mathei C, Buntinx F, Van Vlierberghe H, Francque S, Laleman W, Moreno C, Janssens F, Nevens F, Robaeys G. Arain A, et al. Among authors: nevens f. J Med Virol. 2016 Jan;88(1):94-9. doi: 10.1002/jmv.24308. Epub 2015 Jul 21. J Med Virol. 2016. PMID: 26121975
496 results